Tenofovir alafenamide (TAF) is a novel investigational prodrug of tenofovir (TFV) that permits enhanced delivery of TFV into peripheral blood mono-nuclear cells (PBMCs) and lymphatic tissues. A critical step in the intracellular metabolic activation of TAF is mediated by the lysosomal protease cathepsin A (CatA). Here, we investigated CatA levels together with intracellular metabolism and antiretroviral activity of TAF in primary CD4+ T-lymphocytes (CD4s) and monocyte-derived macrophages (MDMs) isolated from a demographically diverse group of blood donors.
Methods
CD4s and MDMs were prepared from fresh PBMCs. CatA levels were quantified in cell extracts by monitoring TAF hydrolysis using HPLC. Intracellular TAF metabolites were quantified by HPLC combined with mass spectrometry. Antiviral activities in activated CD4s and MDMs were determined using HIV-1 single-cycle reporter and p24 antigen production assays, respectively.
Results
The levels of CatA and intracellular TAF metabolites differed minimally in CD4s and MDMs among 13 tested donors. TAF was >600-fold and 80-fold more potent than parent TFV in CD4s and MDMs, respectively, and its relative range of antiviral activity across all tested donors was comparable to that of other HIV-1 reverse transcriptase inhibitors, with mean ±sd (range) EC50 values of 11.0 ±3.4 (6.6–19.9) nM and 9.7 ±4.6 (2.5–15.7) nM in CD4s and MDMs, respectively.
Conclusions
These results indicate consistent intracellular metabolism and antiretroviral potency of TAF in relevant target cells of HIV-1 infection across multiple donors of variable gender, age and ethnicity, supporting further clinical investigation of TAF.
References
1.
BalzariniJ., HolyA., JindrichJ.Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother1993; 37: 332–338.
2.
BalzariniJ., AquaroS., PernoC.F., WitvrouwM., HolýA., De ClercqE.Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun1996; 219: 337–341.
3.
PalmerS., MargotN., GilbertH., ShawN., BuckheitR., MillerM.Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Res Hum Retroviruses2001; 17: 1167–1173.
4.
KrejčováR., HorskáK., VotrubaI., HolýA.Phosphorylation of purine (phosphonomethoxy)alkyl derivatives by mitochondrial Amp kinase (Ak2 type) from L1210 cells. Collect Czech Chem Comm2000; 65: 1653–1668.
5.
RobbinsB.L., WilcoxC.K., FridlandA., RodmanJ.H.Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy2003; 23: 695–701.
6.
SuoZ., JohnsonK.A.Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J Biol Chem1998; 273: 27250–27258.
7.
CherringtonJ.M., AllenS.J., McKeeB.H., ChenM.S.Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2 phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma. Biochem Pharmacol1994; 48: 1986–1988.
8.
DeeksS.G., Barditch-CrovoP., LietmanP.S.Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother1998; 42: 2380–2384.
9.
LeeW.A., MartinJ.C.Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res2006; 71: 254–259.
10.
AntoniouT., Park-WyllieL.Y., TsengA.L.Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy2003; 23: 29–43.
11.
GrimS.A., RomanelliF.Tenofovir disoproxil fumarate. Ann Pharmacother2003; 37: 849–859.
12.
PermpalungN., PutcharoenO., AvihingsanonA., RuxrungthamK.Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother2012; 13: 2301–2317.
13.
EisenbergE.J., HeG.X., LeeW.A.Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids2001; 20: 1091–1098.
14.
LeeW.A., HeG.X., EisenbergE.Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother2005; 49: 1898–1906.
15.
LeeW.A., HeG., MulatoA.In vivo and in vitro characterization of GS 7340, an isopropylalaninyl phenyl ester prodrug of tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues.9th Conference on Retroviruses and Opportunistic Infections. 24–28 February 2002, Seattle, WA, USA. Poster 384-T.
16.
CallebautC., MargotN.A., MillerM.D.Resistance and potency of GS-7340, a next-generation tenofovir prodrug. Antivir Ther2012; 17Suppl 1: A57.
17.
RuaneP.J., DejesusE., BergerD.Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide (TAF) as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr2013; 63: 449–455.
18.
ZolopaA., OrtizR., SaxP.Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment.20th Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 99LB.
19.
MargotN., LiuY., BabusisD., MillerM.D., CallebautC.Antiviral activity of tenofovir alafenamide (TAF) against major NRTI-resistant viruses: improvement over TDF/ TFV is driven by higher TFV-DP loading in target cells.International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. 4–8 June 2013, Toronto, Canada. Abstract 23.
20.
BirkusG., WangR., LiuX.Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother2007; 51: 543–550.
21.
BirkusG., KuttyN., HeG.X.Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol2008; 74: 92–100.
22.
BirkusG., BamR.A., FreyC.R.Intracellular activation pathways for GS-7340 and the effect of antiviral protease inhibitors.19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Abstract J-115.
23.
SatakeA., ItohK., ShimmotoM., SaidoT.C., SakurabaH., SuzukiY.Distribution of lysosomal protective protein in human tissues. Biochem Biophys Res Commun1994; 205: 38–43.
24.
ChapmanH., KernanM., PrisbeE.Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids2001; 20: 621–628.
25.
Van RompayK.K.A., Durand-GasselinL., BrignoloL.L.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother2008; 52: 3144–3160.
26.
YeeJ.K., FriedmannT., BurnsJ.C.Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol1994; 43: 99–112.
27.
SchackerT., LittleS., ConnickE.Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis2001; 183: 555–562.
28.
FauciA.S.Immunopathogenesis of HIV infection. J Acquir Immune Defic Syndr1993; 6: 655–662.
29.
BiancottoA., IglehartS.J., VanpouilleC.HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood2008; 111: 699–704.
30.
PaceM.J., GrafE.H., AgostoL.M.Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog2012; 8: e1002818.
31.
SchmidH., SauerbreiR., SchwarzG., WeberE., KalbacherH., DriessenC.Modulation of the endosomal and lysosomal distribution of cathepsins B, L and S in human monocytes/ macrophages. Biol Chem2002; 383: 1277–1283.
32.
DelaugerreC., RoudiereL., PeytavinG., RouziouxC., ViardJ.P., ChaixM.L.Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol2005; 32: 241–244.
33.
WhiteK.L., ChenJ.M., FengJ.Y.The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther2006; 11: 155–163.
34.
Sluis-CremerN., SheenC.W., ZelinaS., TorresP.S., ParikhU.M., MellorsJ.W.Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother2007; 51: 48–53.
35.
SilicianoJ.D., SilicianoR F.HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS2013; 8: 318–325.
36.
CihlárT., RosenbergI., VotrubaI., HolýA.Transport of 9-(2-phosphonomethoxyethyl) adenine across plasma membrane of HeLa S3 cells is protein mediated. Antimicrob Agents Chemother1995; 39: 117–124.
